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ABSTRACT 
In this project, we systematically use several computational techniques such as charge 
optimization and component analysis to study molecular recognition and binding in the chronic 
myeloid leukemia (CML) drug systems. Using CML drugs and their biological target, the Bcr-
Abl oncoprotein, we systematically conduct a comparative analysis on five CML drugs bound to 
both the wild-type (WT) and T315I mutant Abl kinase. While early generation drugs (imatinib, 
nilotinib, and dasatinib) interact with Thr315 via a hydrogen bond, novel drugs ponatinib and 
PPY-A bypass interacting with Thr315 altogether. With the mutation to Ile at position 315, early 
generation drugs may experience a significant loss in favorable binding due to loss of 
electrostatic interaction and introduction of steric hindrance. To investigate the differential 
binding of these drugs to the WT and mutant, we optimize each of the drugs to the Abl kinase, 
allowing us to study how each drug binds to the native form. We also optimize PPY-A and 
ponatinib to the mutant T315I, comparing this charge distribution with the one generated from 
optimizing to the native form. Using component analysis, we identify chemical moieties of each 
drug that contribute favorably or unfavorably to the electrostatic free energy of binding. Taken 
together, we hope that by studying CML drugs, we will gain some insight into the larger picture 
of electrostatic binding interaction and potentially provide future direction for rational drug 
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INTRODUCTION 
Currently representing over 15% of all adult leukemias, chronic myelogenous leukemia 
(CML) is a cancer affecting white blood cells with onset in adulthood.1 With a five-year survival 
rate of about 60%, CML is caused by a genetic defect in haematological stem cells (HSC).1-2 A 
chromosomal translocation between chromosomes 9 and 22 generates an abnormal “Philadelphia 
chromosome,” resulting in fusion of the breakpoint cluster (BCR) gene and c-Abl gene.  The 
fused Bcr-Abl oncoprotein lacks an auto-regulatory domain that c-Abl kinase relies on, 
promoting unregulated tyrosine kinase activity. Abnormal expression of the oncoprotein forces 
the bone marrow to produce an uncontrolled proliferation of leukemic cells.  
As the current frontline therapy against CML, imatinib (Gleevec or STI571; Novartis 
Pharma AG) is a tyrosine kinase inhibitor (TKI) and offers patients a long survival rate with 
potent efficacy.2,3 While treatment with imatinib successfully induces complete cytogenetic 
response in over 80% of patients in early stages of CML, the treatment is much less effective 
with patients in advanced stages.4 Unfortunately, the remaining 20% of patients may experience 
relapse and develop resistance to imatinib.3,5 
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An understanding of the Abl kinase binding site and inhibitors’ binding mechanism is 
essential to the construction of novel CML drugs. Multiple crystallographic studies have 
contributed to the understanding of Abl kinase binding and drug resistance mechanisms. 2,3,6,7,8 
Bcr-Abl kinase is a tyrosine kinase, which binds to ATP and catalyzes the phosphorylation of a 
tyrosine hydroxy group. The Bcr-Abl kinase is activated upon interaction with a receptor on the 
extracellular domain of the kinase. Because the Bcr-Abl kinase phoshorylates many substrates 
and does not depend on ligand binding for activation, most TKIs available target the ATP 
binding site. Unfortunately, because Abl kinase is only one of many structurally similar tyrosine 
kinases, it is difficult to design a TKI that binds specifically and tightly to the correct kinase. 
Through high throughput screening, large compound databases, and structure-activity studies, 
Novartis successfully produced imatinib, a potent and competitive inhibitor of Bcr-Abl.6 
Imatinib is a DFG-out inhibitor, which binds only to the inactive conformation of the Abl 
kinase domain.2 In this conformation, the hydrophobic pocket in the Abl kinase domain differs 
from that of other tyrosine kinases. The Asp-Phe-Gly (DFG) loop in the active site changes upon 
inhibitor binding, inactivating the Abl kinase.9 For selectivity, kinase inhibitors take advantage 
of the different shapes and volumes of hydrophobic pockets of different kinases.6 In the same 
way, imatinib utilizes the enlarged, extensive hydrophobic pocket resulting from the inactive 
conformation of Abl kinase domain, making imatinib highly specific and potent against the Bcr-
Abl kinase. Imatinib binds to the Abl kinase domain via multiple hydrogen bonds and van der 
Waals interactions, including interaction with residues Met 318, Thr 315, Glu 286, Ala 38, Ile 
360, His 361, Val 299, Ala 269, Val 256, Phe 382, Leu 248, Leu370 and Phe 317.6,10  
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Figure 2. Binding of imatinib (green) to Abl kinase (magenta). Potential hydrogen bonds are 
displayed in red dotted lines. Interacting residues are labeled and highlighted. 
 
A major barrier to imatinib therapy is increasing drug resistance and relapse in patients.5 
While the mechanisms of drug resistance can include gene amplification of the tyrosine kinase, 
most result from point mutations.5, 11 These point mutations alter amino acid residues within the 
Abl domain, interfering with drug binding while maintaining ATP-binding and protein 
phosphorylation capabilities. Over twenty-five imatinib-resistant point mutations of the 
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patients. Figure 3 shows the most common point mutations in the Abl domain. Most of these 
point mutations occur in the binding interface, introducing steric hindrance or favoring the active 
conformation of the kinase.2 
 
Figure 3. Common point mutations at the Abl kinase (magenta) binding interface. Binding 
interface residues are shown in gray and bound drug is shown in red. Commonly mutated amino 
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Several second generation TKIs have emerged based on knowledge derived from crystal 
structure information.11-12,13 Novartis chemists successfully modified imatinib through structural 
biology and rational drug design strategies, altering the metylpiperazinyl group of imatinib.14 
The resulting drug, nilotinib (Tasigna or AMN107, Novartis Pharma AG), binds with higher 
affinity to Bcr-Abl kinase and also recognizes all mutants except the gatekeeper mutant T315I.15 
Bristol-Myers Squibb Company developed another second generation TKI, dasatinib (Sprycel or 
BMS-354825, Bristol-Myers Squibb Company), from a different chemical scaffold based on 
another tyrosine kinase SRC.5 Like nilotinib, dasatinib displayed more potency and activity 
against imatinib-resistant Bcr-Abl mutants, but also was unable to treat patients with the T315I 
mutation. Unlike nilotinib, dasatinib is a DFG-in inhibitor, which binds to the active form of the 
Abl kinase, much like ATP or ATP-analogs.9 Figures 1b and 1c show nilotinib and dasatinib 
respectively.  
While these second generation drugs show increased affinity to most mutations, they 
remain ineffective against a common mutation among patients: the binding site gatekeeper T315I 
and related T315A mutation.10,16 As DFG-out inhibitors, imatinib and nilotinib bind 
competitively at the ATP binding site. A major component of these inhibitors’ success is the key 
hydrogen bond formed with the side chain of threonine 315, the gatekeeper at the back of the 
ATP binding site. With the T315I mutation, isoleucine’s bulkier side chain blocks inhibitor entry 
into an adjacent hydrophobic pocket and forfeits the hydrogen bond, introducing steric hindrance 
and significantly reducing potency and selectivity.17  
As patients relapse and develop further resistance after treatment with these second 
generation TKIs, there remains a need for novel treatment that is not only potent and specific to 
Bcr-Abl but also active against mutant Bcr-Abl kinases including the T315I mutant. Currently, 
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multiple pharmaceutical companies are working to develop third generation drugs that will 
inhibit the Bcr-Abl kinase while maintaining the high specificity existing inhibitors have towards 
the tyrosine kinase.1 Among these third generation drugs, Ariad Pharmaceuticals’ ponatinib has 
proven potent against both native and mutant forms of Bcr-Abl and is currently undergoing 
phase 3 trials.1,9,18,19 In particular, to avoid the steric clash with the bulky side chain of 
gatekeeper residue isoleucine 315, ponatinib utilizes a linear triple bond linkage. Figure 4a 
shows the structure of ponatinib. By bypassing the original steric hindrance introduced by 
isoleucine, ponatinib is able to interact with the hydrophobic pocket while maintaining favorable 
hydrogen bonding interactions, including interactions with residues Glu 286, Met 318, His 361, 
and Ile 360 on the WT and mutant Bcr-Abl.17 Furthermore, ponatinib also distributes its binding 
interactions over a wide range of residues on Abl kinase’s binding interface. This ensures that 
single point mutations are unlikely to significantly affect affinity of the drug-target interaction.17  
 
Figure 4. Structure of third generation drugs: A) Ponatinib. B) PPY-A. Chemical moieties 
are colored. 


















	   12	  
Another third generation drug, a pyyropyridine inhibitor PPY-A (SGX Pharmaceuticals), 
binds to T315I as well as the native Abl kinase.1 Unlike ponatinib, PPY-A bypasses the steric 
clash of T315I gatekeeper residue by simply avoiding interaction with the hydrophobic pocket. 
Like dasatinib, PPY-A binds to the active conformation of the Abl kinase domain as a “DFG-in” 
inhibitor, rather than the inactive conformation. However, unlike dasatinib, PPY-A interacts with 
the glycine-rich loop in an important hydrogen bond, overcoming the T315I mutation.1 Figure 4b 
shows the structure of PPY-A.  
Rational drug design has aided the development of each of these CML tyrosine kinase 
inhibitors. Developed in the 1990s, imatinib is considered one of the first rationally designed 
drugs to be approved for cancer therapy.14 The discovery of oncogenes, or cancer-related genes, 
gave pharmaceutical companies a tangible biological target to consider when developing small 
molecule inhibitors.20 In the case of CML, identification of the Abl kinase provided a clear target 
to which drugs could be optimized. Once a target molecule in a biologically relevant pathway is 
chosen, a lead compound is needed to begin the drug design process. Traditionally, lead 
compounds were the result of random screening using in vitro or in vivo experiments.19 
However, recent developments in technology, including X-ray crystallography, NMR, docking 
tools, and computational chemistry, have increased the efficiency of drug design, enabling 
pharmaceutical companies to select and optimize lead compounds.19, 21 With imatinib, Novartis 
was able to utilize high throughput screening to identify a derivative of phenylaminopyrimidine 
as a potential lead compound for structure-based design.14 Once a lead compound has been 
identified, various tests, both experimental and computational, can then determine the binding 
profile, reactivity, absorptivity, and other pharmacokinetic properties of a potential drug. 
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As illustrated with the various point mutations of Bcr-Abl and subsequent generations of 
TKI, one of the major challenges of drug design is to develop a therapy with both high affinity 
and a tailored specificity profile. To optimize a lead compound, an understanding of the binding 
mechanism and 3D structure of the target is crucial. Furthermore, understanding the determinants 
of binding is essential to rational drug design. For example, to treat CML, imatinib was initially 
developed to bind to only one out of many structurally similar cellular kinases – the Bcr-Abl 
kinase. Thus, imatinib must be designed to avoid off-target binding to minimize toxic side 
effects. Luckily, Novartis scientists were able to utilize the hydrophobic pocket unique to the 
Bcr-Abl kinase domain. However, other drugs, such as those used to treat HIV, must recognize 
multiple mutant variants to combat drug resistance. With emerging point mutations and 
resistance to imatinib, second and third generation inhibitors for CML not only must bind 
specifically to the Bcr-Abl tyrosine kinase rather than other tyrosine kinases, but they also must 
bind to multiple mutant variants of this Bcr-Abl tyrosine kinase. The development of such a 
balance between narrow and broad specificity requires successful understanding of the structural, 
physical, and chemical properties of both target and ligand. As such, with both second generation 
and third generation TKIs as excellent examples, understanding the principles of molecular 
binding and recognition significantly facilitates the design of novel drugs. Developed with 
computational aid and rational drug design strategies, ponatinib is currently in clinical trials but 
show the most promise. It is able to bind to both mutant and native variants of Bcr-Abl while 
maintaining high affinity and low toxicity.  
The development of these drugs has shown that understanding the 3D structure and target 
binding can aid greatly in designing highly specific drugs for treatment of CML. In this study, 
we analyze the binding profile and structures of the CML drug systems, including all three 
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generations of tyrosine kinase inhibitors: imatinib, dasatinib, nilotinib, PPY-A, and ponatinib. 
CML drugs provide a unique framework with which we can explore the molecular determinants 
of binding and recognition in a biological environment. Each drug displays different levels of 
specificity, with imatinib being highly specific to only the native Bcr-Abl and ponatinib being 
promiscuous. All drugs display high affinity binding to the WT Abl kinase and, in the case of 
ponatinib and PPY-A, to the mutant Abl kinase.  
Computation has recently proved to be a powerful tool in the design of many other drugs 
requiring a tailored specificity profile, including drugs targeting the rapidly mutating HIV.22,23 
Among the computational methods, molecular dynamics simulations,24,25,26,27,28 docking 
studies,29,18,30 and studies of electrostatics31,32 have permeated the field of computational 
molecular design. So far, several computational studies have used molecular dynamics 
simulations to focus on the conformational binding of imatinib to the Bcr-Abl kinase fusion 
protein.22, 23 As well, Lin et al. recently implemented an all-atom molecular dynamics simulation 
modeling solvent explicitly to calculate the absolute free energy of binding between imatinib and 
the oncoprotein.26 However, to my knowledge, no study has focused solely and consistently on 
electrostatic complementarity of CML drugs.  
 Thus, to provide further insight into the binding and specificity profile of imatinib and 
other CML drugs, this study uses computational methods to examine the electrostatic portion of 
binding free energy of CML drugs, focusing on the native and T315I gatekeeper mutant Bcr-Abl. 
While other components of binding, such as van der Waals interactions and hydrophobic effects, 
also play crucial roles in binding, electrostatics contribute greatly to specificity and affinity. In 
the context of drug design, electrostatics has proven to be a highly flexible handle to manipulate, 
improving a compound’s specificity or promiscuity.33 Single residues or alterations in the 
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charges on a functional group can significantly impact binding.34,35 Moreover, electrostatics can 
be easily manipulated and studied computationally. In this work, we use charge optimization, a 
theoretical framework developed by Lee, Kangas, and Tidor.36,37 Charge optimization is a 
computational technique that finds the optimal charge distribution on a drug or ligand to 
maximally favor electrostatic interactions. This method has been used to analyze multiple 
systems and to design novel therapeutics.38,39 In particular, Sims et al. successfully utilized 
charge optimization to facilitate kinase inhibitor design for CDK2 and protein kinase A 
systems.38  
While CML drugs have been analyzed extensively using crystallography and, to an 
extent, molecular dynamics simulations, this work is the first to apply charge optimization 
techniques to CML tyrosine kinase inhibitors. Furthermore, to the best of our knowledge, no 
other work has examined these CML drugs comparatively with consistent computational 
methodology. The ability to computationally alter specific moieties of existing drugs to improve 
selectivity or stability can significantly facilitate the drug discovery process, potentially 
impacting whole populations. In our work, we optimize each of five drugs to the Bcr-Abl kinase, 
allowing us to study how each drug binds to the native form. We also optimize PPY-A and 
ponatinib to the mutant T315I, comparing this charge distribution with the one generated from 
optimizing to the native form. Additionally, we apply component analysis to the drug, 
identifying chemical moieties of the drug that contribute favorably or unfavorably to the 
electrostatic free energy of binding. Taken together, we hope that by studying CML drugs, we 
will gain some insight into the larger picture of electrostatic binding interaction and potentially 
provide future direction for rational drug design and battling drug resistance. 
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THEORY 
Introduction 
To conduct a comparative study of CML drugs with the native and mutant Bcr-Abl 
kinase, we use a metric that quantifies a drug’s electrostatic interaction with its receptor(s). In 
particular, we calculate the electrostatic component of the free energy of binding between two 
molecules in a biological environment. Consider a reversible system in which a ligand (in our 
case, the drug) and receptor come together to form a complex: 
Ligand (drug) + receptor D complex 
The Gibbs free energy between the bound and unbound states of the system gives us a handle to 
study the electrostatics of molecular interaction. Multiple factors contribute to the change in 
Gibbs free energy (ΔGtotal): 
ΔGtotal = ΔGelec + ΔGSASA + ΔGvdW + ΔGint 
ΔGelec measures the electrostatic component of Gibbs free energy. ΔGSASA is a function of the 
change in the system’s solvent accessible surface area. It takes into account both the loss of 
dispersion interactions between solute and solvent, and the solvent entropy gain upon binding. 
ΔGvdW measures the changes in van der Waals energy upon complex formation. Finally, ΔGint 
measures the change in internal conformational energy of the system and is a function of 
geometry of the system. Because we assume rigid binding, ΔGint = 0 in our system. 
 In this study, we focus on the electrostatic component of Gibbs free energy, ΔGelec, using 
a continuum electrostatic model. With previously established framework, we can 
computationally calculate and quantify electrostatic interactions, which play a crucial role in 
binding. While the most accurate method to study electrostatic interactions is to solve the 
Schrödinger Equation for a molecule’s electronic wave function and integrate Coulomb’s law 
	   17	  
over the electron density as a function of time, it is impossible to solve for a system with more 
than one electron exactly. Furthermore, it is currently computationally infeasible to solve the 
Schrödinger Equation dynamically with time.  
As our systems are considerably larger than a one-electron system, we approximate 
electrostatic interactions by assigning partial atomic charges to atoms within our molecules. 
Rigid binding is assumed. Rather than calculating the absolute properties of a molecule’s 
electron clouds, especially of those in large molecular systems, partial atomic charges model the 
electron distribution as single, rigid point charges that reflect their physical properties such as 
electronegativity. For example, as a highly electronegative atom, fluorine would be assigned a 
more negative partial atomic charge as it tends to pull in more electron density in a molecule. 
With assigned partial atomic charges, we can then obtain charge distributions for each entity in 
our system and model the electrostatic interactions of binding. To determine partial atomic 
charges for drug molecules, we use a restrained electrostatic potential (RESP) two-stage fitting 
method.40 This method finds the molecular electrostatic potentials at the molecule’s Merz-
Kollman surface using ab initio quantum mechanical calculations. Charges are then fitted to the 
system using a least-squares method to reproduce the electrostatic potentials at each point.41 To 
account for the conformational-dependence of such fitting, RESP-fitting method introduces 
restraints in the form of penalty functions. The goal of such restraints is to minimize the 
magnitude of charges. In the two-stage fitting method, the first stage has the most degrees of 
freedom and weak restraints, to obtain best fits for polar areas of the molecule. The second stage 
holds the polar fixed charges and varies the nonpolar charges to readjust to a forced symmetry. 
This latter stage has strong restraints. 
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Electrostatics and Dielectric Theory 
Even with partial atomic charges obtained, modeling electrostatic interactions between 
biological molecules is difficult. Consider our system of a receptor and ligand in the unbound 
state coming together in water to form a bound complex state. In vacuum, if our receptor 
possesses a positive charge, a negatively charged ligand would bind favorably to the receptor. In 
water, however, the ligand must overcome favorable interactions with the partially positive 
hydrogens of water to reach the receptor and bind to it. Similar, the receptor must overcome 
favorable interactions with the partially negative oxygens of water. Thus, the electrostatic 
interaction between the receptor and ligand is screened by the polar water. 
While it is possible to use molecular dynamics simulations to account for the polarization 
and reorganization of each polar water molecule upon complex formation, it is extremely time 
consuming and computationally costly. Instead, we approximate this effect by modeling water 
implicitly as a dielectric continuum. 
Figure 5. Schematic of our model, showing a receptor, R, and ligand, L, in water (A) and in 
a continuum framework (B). Receptor and ligand show partial atomic charges. 
A	   B	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Here, we present the theory of continuum electrostatics. First, we consider systems in 
vacuum. With the charge distribution of each molecule obtained by RESP fitting or other 
parameterization, we can use the Poisson equation, the fundamental equation of electrostatics, to 
study electrostatic interactions.42  
∇2φ(r) = −ρ(r)
ε0
	   	   	   	   	   (1)	  
The Poisson equation relates potentialφ(r) to the charge distributionρ(r) . Both are functions of 
position, r. The solution to the Poisson equation (1) yields Coulomb’s law when is a 
superposition of point charges: 
φ(r) = kqi
r − r ii
∑      (2) 
q is the value of the jth charge. The electrostatic energy required to bring a charge to a point is 
then simply the potential at that point multiplied by the charge: 
E = qφ      (3) 
Thus, the electrostatic energy of interaction between a pair of charges can be calculated as such: 
E = qφ = kq1q2r − ri
	   	   	     (4) 
where k is the constant 1
4πε0
, and q1 and q2 are respective charge values. ε0 is the permittivity of 
free space constant. 
However, this expression for electrostatic interactions in vacuo is impractical. Rather 
than existing in free vacuum, all systems of biological interest exist in an aqueous solution, 
which we model as a dielectric continuum. Once a medium is introduced to the system, the 
ρ(r)
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electrostatic interactions are weakened, or screened, by a factor of D, the dielectric constant. 
Thus, the Poisson equation becomes: 
∇2φ(r) = −ρ(r)
ε0D
      (5) 
The value of dielectric constants is related to the polarizability of a medium and can be found in 
various textbook references.  
Water is assigned a dielectric constant of 80. The high dielectric constant accounts for the 
polarizability of water. While literature uses a range of values from 2 – 40 for proteins and small 
molecules, a dielectric of 4 can reproduce experimental data.43,44 In general, the more polarizable 
a medium is, the higher the dielectric constant and the stronger the solvent screening is relative 
to a vacuum. Thus, we can think of our system as low dielectric cavities within a high dielectric 
medium. With partial atomic charges assigned throughout the low dielectric molecules in our 
system, we can use the following form of the Poisson Equation to study electrostatic interactions 
in varying dielectric space: 
∇•D(r)∇φ(r) = −ρ(r)
ε0
    (6) 
Note that in this study, we do not take into account salt. However, mobile ions exist in 
our body alongside proteins and drugs. Thus, future studies can use Debye-Hückel theory to 
implicitly account for the additional force field sources generated by the dissolved ions.  
Charge Optimization 
In this section, we will briefly outline a previously established continuum electrostatics 
framework developed by Tidor et al. that allows us to study CML drugs computationally.36,37 
Due to the polar nature of water, biological molecules interact extensively with the solvent. In 
the unbound state, a ligand is surrounded completely by water, which polarizes to interact 
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favorably with the ligand. In order to bind with the receptor, the water molecules at the binding 
interface sacrifice their interactions with the receptor so the ligand can interact with the receptor. 
Complex formation strips away favorable interactions water has with the ligand, thus entailing a 
ligand desolvation penalty. The receptor desolvation penalty similarly accounts for the loss of 
favorable interactions with water upon binding. The interaction term captures the energy of 
complex formation between the ligand and receptor. Figure 6 captures the idea behind these 
terms. 
 
Figure 6. Schematic demonstrating the ligand desolvation penalty and interaction upon 
complex formation. From the unbound to bound state, the ligand’s favorable interaction with 
the dielectric medium (solvent) is replaced with a low dielectric cavity in the shape of the 
binding partner. This yields a desolvation cost. From there, the ligand binds to the receptor, 
replacing the low-dielectric cavity with the receptor containing partial atomic charges. The 
bound state (usually favorable) interaction completes this thermodynamic cycle.  
  
Given these solvent interactions, charge optimization allows us to calculate the optimal 
hypothetical charge distribution of each drug to minimize the electrostatic binding free energy 
toward a given target molecule (recall that the more negative the free energy of binding is, the 
more favorable that interaction is). This technique allows us to find an appropriate balance 
between the desolvation penalties paid by the receptor and ligand upon binding with the 
favorable interaction of the complex. We can then compare the hypothetical optima to the natural 
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charge distribution to identify portions of the drug that could potentially be altered to improve 
binding. Several studies have utilized this computational technique to study small molecules and 
proteins36,39 and aid in the design and analysis of novel drugs.38,45  
Using the continuum electrostatics model and Poisson equation, we can express the 
electrostatic portion of binding as sums of matrix-vector products: 
ΔGelec = ql 'Lql + qr 'Rqr + ql 'Cqr     (7) 
The first term, ql 'Lql represents the ligand desolvation penalty. The second term qr 'Rqr is 
the analogous receptor desolvation penalty. The third term ql 'Cqr accounts for the interaction 
formed upon binding. ql  and qr  are vectors of the partial atomic charges on ligand and receptor 
respectively. L  and R are the matrices of ligand and receptor desolvation unit potentials, 
respectively, derived from solving the Poisson Equation (once in the bound and unbound states 
for each charge on either partner). L and R describe the loss of solvent interaction with the ligand 
or receptor. They also account for the change in screened interaction between the charges within 
the ligand or receptor upon complex formation. The matrices are in units of energy per charge 
per charge. Thus, to obtain desolvation energies, we multiple the matrix by the charge vector and 
its transpose. Finally, C is the matrix of unit interaction potentials between the ligand and 
receptor. C accounts for the screened Coulombic interactions between the ligand and receptor 
upon binding.  
The desolvation matrices, L and R, are positive semidefinite, which means that they have 
nonnegative eigenvalues. They are symmetric with dimensions equal to the number of partial 
atomic charges on each molecule. Each ijth element of the matrix captures the ½ potential 
difference per unit charge between the bound and unbound states in the interaction of the ith and 
jth charge on the molecule. When calculating the potential of a charge interacting with its own 
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reaction field using linear response theory; the entropic penalty incurred is half of the unit 
potential. Thus, the diagonal elements of these desolvation matrices measure half of the change 
in potential per charge at each point i in the molecule between the bound and unbound states. 
The factor of ½ accounts for the entropic penalty incurred. Additionally, each off-diagonal 
element is divided by 2 to avoid double-counting.  
C is rectangular, with dimensions of m, the number of charges on the receptor, by n, the 
number of charges on the ligand. The ijth element in the complex interaction matrix measures the 
potential difference between the bound and unbound states in the interaction of the ith charge on 
the receptor and the jth charge on the ligand. L, R, and C are independent of the charge 
distribution of the ligand and receptor and depend only on the shapes of the molecules and 
locations of the partial atomic charges. 
Recall that we aim to find a hypothetical optimal charge distribution for our drug or 
ligand: ql is treated as a variable. We can treat the above ΔGelec equation as a simple quadratic 
optimization problem: 
ΔGelec = ql 'Lql + qr 'Rqr + ql 'Cqr  
As with finding any maxima or minima, we can take the derivative of ΔGelec with respect to ql 
and set it to 0.  Because L is positive semidefinite, a plot of ΔGelec vs ql will yield an upward 
facing multi-dimensional paraboloid.  
∂ΔGelec
∂ql
= 0 = 2ql ,opt 'L+Cqr 	   	   	   	   (8)	  
Thus, we can find the minimum of ΔGelec by solving for ql,opt. 
ql,opt = −0.5L−1Cq r 	   	   	   	   	   (9)	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Finally, we can substitute ql,opt – the optimal charge distribution that yields a minimal ΔGelec – 
into our Gibbs free energy equation to obtain an optimal binding free energy:  
ΔGelec,opt = ql ,opt 'Lql ,opt + qr 'Rqr + ql ,opt 'Cqr 	   	   	   (10)	  However,	   the	  completely	  unconstrained	  optimization	  derived	  here	  may	  lead	  to	  physically	  unrealistic	  results.	  If	  the	  binding	  free	  energy	  is	  not	  very	  sensitive	  to	  certain	  charges	  on	  the	  drug,	   those	   charges	   may	   optimally	   have	   high	   charge	   magnitudes	   to	   achieve	   only	   minor	  gains	  in	  affinity.	  To	  address	  this,	  constraints	  are	  often	  used	  to	  yield	  more	  realistic	  results.	  In	  this	  study,	  we	  constrain	  the	  charge	  magnitude	  of	  each	  atom	  to	  be	  less	  than	  1.0e.	  Where	  appropriate,	  we	  also	  apply	  various	  constraints	  to	  the	  overall	  monopole	  of	  the	  drug.	  	  	   We	  note	  that,	  to	  apply	  charge	  optimization,	  there	  is	  no	  need	  to	  explicitly	  calculate	  R	  or	  C.	  Instead,	  we	  calculate	  a	  Cqr	  vector	  and	  a	  receptor	  desolvation	  qr’Rqr	  term.	  	  
Component	  Analysis	  We	   also	   use	   component	   analysis	   to	   study	   binding	   in	   this	   system.	   Component	  analysis	  allows	  us	  to	  evaluate	  the	  contributions	  of	  individual	  chemical	  moieties	  or	  residues	  to	   the	   free	   energy	  of	  binding.46	  By	  applying	   component	   analysis	  on	   chemical	  moieties	  or	  functional	  groups	  on	  the	  drug,	  we	  can	  potentially	  identify	  portions	  of	  the	  drug	  that	  could	  be	  modified	   to	   improve	   the	   electrostatics	   of	   binding.	   Similarly,	   we	   can	   apply	   component	  analysis	   on	   residues	   on	   the	   Abl	   kinase	   to	   quantify	   their	   role	   in	   binding.	   By	   setting	   the	  charges	  of	   a	   chemical	  moiety	  on	   the	  drug	  or	   amino	  acid	  on	   the	   receptor	   to	   zero,	  we	   can	  reevaluate	  Equation	  (7)	   to	  obtain	  a	  new	   free	  energy	  of	  binding	  with	   those	  charges	  set	   to	  zero;	  we	  define	  a	  ΔΔGmoiety to assess the effect of that moiety to binding.  
ΔΔGmoiety = ΔGmoiety ,zeroed −ΔGorig 	   	   	   (11)	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A	   positive	   ΔΔGmoiety indicates that the moiety contributes favorably to binding. A negative 





 Seven crystalline structures of CML drugs bound to the wild-type (WT) or mutant 
structure of Abl kinase were used: Imatinib in complex with WT Abl kinase (PDB ID 2HYY2), 
Nilotinib in complex with WT Abl kinase (3CS915), Dasatinib in complex with WT Abl kinase 
(2GQG12), Ponatinib in complex with WT Abl kinase (3OXZ17), Ponatinib in complex with 
T315I mutant Abl kinase (3IK317), PPY-A in complex with WT Abl kinase (2QOH1), and PPY-
A in complex with T315I mutant Abl kinase (2Z601). Table 1 summarizes the structures used, 
along with resolutions and number of water molecules retained. All seven structures contained 
multiple complexes in the unit cell. The complex with the least missing density close to the 
binding site were chosen. Residues adjacent to missing density regions were patched with 







2HYY2 2.4 2 
3CS915 2.21 13 
2GQG12 2.4 20 
3OXZ17 2.2 15 
3IK317 1.9 24 
2QOH1 1.95 20 
2Z601 1.95 19 
Table 1. Structures used from Protein Data Bank. 
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To prepare the structure for use in our study, we eliminated all water molecules that had 
less than three potential hydrogen bonding interactions or were more than 3.3 Å away from 
either binding partner. Remaining explicit waters were assigned to the receptor during 
calculations. Explicit ions were also eliminated. After careful examination, the amide group on 
the side chain of asparagine and glutamine were flipped as necessary based on any potential 
hydrogen bonding interactions in the proximity. As well, the imidazole group of each histidine 
was flipped as necessary; each histidine was also assigned as the epsilon or delta tautomer based 
on potential hydrogen bonds with surrounding residues or drug. In complex 2GQG, a 
phosphotyrosine was converted to a regular tyrosine residue.  
 To obtain partial atomic charges for the drug molecules, the geometry of each drug 
molecule was first optimized with Gaussian 200347 using Hartree-Fock theory and 6-31G basis 
set. The electronic wave functions and electrostatic potentials at the Merz-Kollman surface were 
obtained using Hartree-Fock level theory and 6-31G* basis set.48 The resulting electrostatic 
potentials were then used in a two-stage fitting RESP method40 to obtain charge distribution for 
drug structures.  
 Hydrogen atoms were incorporated into each structure using CHARMM’s49 hydrogen-
building (HBUILD) facility.50 This study used the CHARMm22 force field and parameter set.41 
CHARMm22 atom types were assigned to each atom in the drugs. Because several atoms in 
2QOH, 2GQG, and 3OXZ lacked parameters, alternative but similar atom types were assigned. 
Because their positions were fixed during structure preparation and calculations, assigning an 
alternative atom type is not expected to have significant effects in the structure preparation 
process.  
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Charge Optimization 
 To obtain all matrix and vector components necessary for charge optimization (described 
in the theory section), a finite difference solver51 was used to solve the Poisson Equation. The L 
matrix, Cqr vector, and receptor desolvation penalty (qr’Rqr) were obtained for each complex. 
To solve the Poisson Equation, a cubic grid ranging from (193 x 193 x 193) to (201 x 201 x 201) 
grid points was used to maintain a consistent grid resolution of 6 grids/Å for each complex. 
Three stages of focusing were used to solve the Poisson Equation: the structure first occupied 
23% of the grid, followed by 92% of the grid, and finally 184% of the grid. The structure was 
centered at the binding interface. PARSE radii were used for all atoms; Parm99 AMBER van der 
Waals radii were used for F atoms.52 The dielectric boundary of the protein and drug was 
determined using a 1.4 Å probe sphere.53 A dielectric constant of 4 was used for proteins and 
small molecules. 
 The General Algebraic Modeling System54 was used to conduct all charge optimization 
calculations subject to constraints. In all instances, charge magnitudes were constrained to be 
1.00e. Because all drugs studied naturally have an overall charge of 0, the drug monopole was 
constrained to be 0 to enable a direct comparison. Follow-up optimizations with additional non-
zero total monopole constraints were performed as well.  
Component Analysis To	  quantify	  the	  contributions	  of	  certain	  moieties	  of	  the	  drug	  to	  electrostatic	  portion	  of	   binding,	  we	   can	   set	   the	   atoms	   of	   that	  moiety	   to	   zero	   and	   calculate	   the	   free	   energy	   of	  binding.	   In	  equation	  (7),	  qL	  elements	  corresponding	  to	  a	  moiety’s	  atoms	  were	  set	  to	  zero	  and	  the	  free	  energy	  of	  binding	  was	  reevaluated.	  Matlab	  (The	  Mathworks,	  Inc.,	  Natick,	  MA)	  was	  used	  to	  execute	  drug	  component	  analysis	  calculations.	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In	   applying	   component	   analysis	   to	   the	   receptor’s	   residues,	   because	   we	   did	   not	  calculate	  explicit	  R	  matrix	  elements,	  we	  set	  the	  charges	  on	  the	  residue	  to	  zero;	  the	  binding	  free	  energy	  was	  reevaluated.	  	  
Sensitivity Analysis 
 Diagonal L matrix elements approximately represent the sensitivity of the free energy of 
binding to changes in charge on that atom.55 These diagonal elements were extracted; radii sizes 
of atoms were scaled accordingly. 
Figure Generation  




In this study, charge optimization, component analysis, and sensitivity analysis were used 
to probe the electrostatic determinants of binding in CML drug complexes. This section presents 
the data obtained from these computational techniques. For each drug studied, three types of 
figures are shown. Figures 7a, 9a, 12a, 15a, and 19a show the structure of the drug colored by 
atom type and labeled to facilitate discussion of the data. Figures 7b, 9b, 12b, 15b, and 19b 
depict results of component analysis, with the chemical moieties separated by pink bonds. For 
ponatinib and PPY-A, part c of the figure shows component analysis results of the mutant Abl 
kinase complex. Chemical moieties are labeled in parentheses to facilitate discussion of moieties. 
Key residues interacting via hydrogen bonds are shown in yellow.  
Figures 2, 10, 13, 16, and 20 also depict the binding interface and key interactions with 
Abl kinase for each drug. Drugs are highlighted in green and colored by atom type; potential 
hydrogen bonds are displayed in red dotted lines. Interacting residues are also labeled.  
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Charge optimization and sensitivity analysis results are shown in figures 8, 11, 14, 17, 18, 
21, and 22. Part a of each panel shows the drug’s optimal charge distribution. Part b of each 
panel shows the difference in optimal and natural charges on the drug.  
 




Figure 7. Structure of imatinib and component analysis show favorable and unfavorable 
moieties of the drug. A) Structure of imatinib colored by atom type. Atoms are labeled. B) 
Component analysis was conducted on each chemical moiety (separated by pink bonds and 
labeled with numbers). Favorability of moiety is indicated with color and intensity. White 
represents neutral moieties, red represents unfavorable moieties, and blue represents favorable 
moieties. ΔΔGmoiety are labeled.  
 
Component analysis (figure 7b) shows that much of imatinib contributes favorably to 
binding (~1 kcal/mol to 2 kcal/mol). Moiety 1, or the methylpiperazine group, contributes most 
66G = -0.181 kcal/mol
66G = -0.6815 kcal/mol
66G = 1.049 kcal/mol
66G = 1.793 kcal/mol 66G = 1.908 kcal/mol
66G = 1.815 kcal/mol
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unfavorably to binding, with a ΔΔGmoiety,1 = -1.968 kcal/mol. Groups 3, 5, and 7 all form 
hydrogen bonds with residues on the receptor Abl kinase (refer to Figure 2). However, only 
groups 3 and 7 contribute favorably to binding (ΔΔGmoiety,3 = 1.793 kcal/mol, ΔΔGmoiety,7 = 1.968 
kcal/mol). While the amine (5) does form a hydrogen bond with the side chain of Thr315, it is 
slightly unfavorable to binding (ΔΔGmoiety,5 = -0.6815 kcal/mol). 
 
 
Figure 8. Charge optimization results and sensitivity analysis of imatinib in complex with 
WT Abl. A) Optimal charge distribution of imatinib when bound to WT Abl. Charges range 
from -1.0e (red) to 1.0e (blue). Hydrophobic atoms are colored in white. Total charge on drug is 
constrained to be 0. B) Charge differences of imatinib bound to WT between optimal and natural 
charges. Red indicates atoms that are too positive and would be more optimal if they were more 
negative. Blue indicates atoms that are too negative and would be more optimal if they were 
more positive. Radii in figures A and B correspond to sensitivity of free energy to changes in 




















Wants to be positiveWants to be negative
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Figure 8a shows the optimal charge distribution of imatinib in complex with WT Abl 
kinase. Upon charge optimization, the free energy of binding improved by 10.39 kcal/mol. Refer 
to Table 2 for all binding calculations and optimization results. The drug is largely hydrophobic 
at its optimal charge distribution (figure 8a). However, a few atoms on imatinib are highly 
charged when optimal. Figure 8b shows the difference between optimal and natural charge 
distributions. Interestingly, both the methylpiperazine group and the aromatic group (7) have 
high magnitude charges when optimal. The methylpiperazine’s natural charge distribution is far 
from optimal while group 7 is closer to optimal. In particular, one of the hydrogens (H62) on the 
methyl group of moiety 1 would be charged when optimal. Furthermore, N29 in that same 
moiety is positive in its optimal charge distribution, rather than negative; thus, the charge on N29 
is far from optimal.  
In group 7, N5 has a highly negative partial atomic charge and is already optimal. C11, 
which is sp2 hybridized and bound to three nitrogens, is originally positive. However, in its 
optimal distribution, those atoms (C11, N10, N12, N13) are hydrophobic. Finally, the amide 
group (moiety 3, atoms N20, C21, O30, H41) that interacts with the side chain carbonyl of 
Glu286 and backbone NH of Asp381 via hydrogen bonds is highly optimal (figure 8b). The free 
energy of binding show high sensitivity to changes in the partial charges of the atoms directly 
interacting in the hydrogen bond (H41 and O30) (figure 8).  
While these figures show charge optimization of imatinib subject to the constraint that 
the drug monopole be 0.0e, an unconstrained optimization found that the optimal monopole for 
the drug to be close to 1.67e. The free energy of binding improved by 12.726 kcal/mol (ΔG = 
1.092 kcal/mol), which yielded an additional gain of 2.336 kcal/mol from the constrained 
optimization. The total charge of the optimal drug is quite high and warrants further 
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investigation. Table 2 at the end of the results section lists all optimizations and their free energy 
calculation results. 
Nilotinib 




Figure 9. Structure of nilotinib and component analysis show favorable and unfavorable 
moieties of the drug. A) Structure of nilotinib colored by atom type. Atoms are labeled. B) 
Component analysis was conducted on each chemical moiety (separated by pink bonds). 
Favorability of moiety indicated with color and intensity. White represents neutral moieties, red 
represents unfavorable moieties, and blue represents favorable moieties. ΔΔGmoiety are labeled. 
 
Nilotinib makes hydrogen bonds with the same key residues that imatinib does (figure 10 
below shows the binding site interactions with Abl kinase). Component analysis results (figure 
9b) show that no moiety of nilotinib is particularly unfavorable. All unfavorable moieties have 
66G = 0.739kcal/mol
66G = 0.484 kcal/mol
66G = -0.471 kcal/mol
66G = -0.025 kcal/mol
66G = 2.334 kcal/mol
66G = 0.069 kcal/mol
66G = -0.220 kcal/mol
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ΔΔGmoiety magnitudes of less than 0.5 kcal/mol. Moreover, the amide group (moiety 5) 
contributes very favorably to binding (ΔΔGmoiety,5 = 2.334 kcal/mol). No other chemical moiety 
contributes as strongly to binding. This amide group, like the amide in imatinib, interacts with 
both Glu286 and Asp381. The pyridine N (moiety 1) interacts via a hydrogen bond with the 
backbone of Met318 (figure 10).  
 
Figure 10: Binding of nilotinib (green) to Abl kinase (magenta). Potential hydrogen bonds are 
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Figure 11. Charge optimization results and sensitivity analysis of nilotinib in complex with 
WT Abl. A) Optimal charge distribution of nilotinib when bound to WT Abl. Charges range 
from -1.0e (red) to 1.0e (blue). Hydrophobic atoms are colored in white. Total charge on drug is 
constrained to be 0. B) Charge differences of nilotinib bound to WT between optimal and natural 
charges. Red indicates atoms that are too positive and would be more optimal if they were more 
negative. Blue indicates atoms that are too negative and would be more optimal if they were 
more positive.  
 
 Nilotinib’s charge distribution was optimized to bind to WT Abl kinase. Figure 11a 
shows nilotinib’s optimal charge distribution, which yielded an improvement in binding of 4.547 
kcal/mol. Figure 11a shows that most of the drug is hydrophobic when optimized. While C37, 
N38, and C36 of moiety 1 are polar when optimal, they are already quite close to their optimal 
partial atomic charges (figure 11b). 
Likewise, the amide (moiety 5) also contains high magnitude partial atomic charges 
(atoms H60, N3, C2, O1). These atoms interact via hydrogen bonds with the side chain carbonyl 
1.5e1.0e-1.5e 1.0e0.0e-1.0e
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of Glu286 and backbone NH of Asp381. Figure 11b shows that the amide’s natural charges are 
optimal. Our sensitivity analysis shows that the free energy of binding is highly sensitive to 
change in charge on the carbonyl of the amide.  
Interestingly, moieties 2 (pyrimidine) and 3 (amine) are the furthest from optimal. While 
the hydrogen of amine, H61, that interacts with the side chain OH of Thr315 is close to optimal, 
N27 and C28 is entirely hydrophobic in the optimal charge distribution. N27 and C28 are almost 
1.0e far from optimal.  
An unconstrained optimization found the optimal monopole for the drug to be 1.60e. This 
yielded an improvement in the free energy of binding of 6.971 kcal/mol, which is a 2.424 




Figure 12. Structure of dasatinib and component analysis show favorable and unfavorable 
moieties of the drug. A) Structure of dasatinib colored by atom type. Atoms are labeled. B) 
Component analysis was conducted on each chemical moiety (separated by pink bonds). 
Favorability of moiety indicated with color and intensity. White represents neutral moieties, red 
represents unfavorable moieties, and blue represents favorable moieties. ΔΔGmoiety are labeled. 
66G = 0.183 kcal/mol
66G = -0.336 kcal/mol
66G = 0.758 kcal/mol
66G = 0.778 kcal/mol
66G = 1.438 kcal/mol
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 Dasatinib interacts with both Thr315 and Met318 via hydrogen bonding interactions. 
Figure 13 (below) shows key hydrogen bonding interactions; Met318 makes two hydrogen bonds 
with dasatinib, suggesting that Met318 is a major contributor to binding. Component analysis 
(figure 12b) shows that moiety 4, which interacts with Met318, contributes very favorably to 
binding (ΔΔGmoiety,4 = 1.428 kcal/mol). We analyze Met318 in more detail in the discussion 
section. However, like with imatinib and nilotinib, the amide group that makes a hydrogen bond 
with Thr315 contributes unfavorably to binding (ΔΔGmoiety,5  = -2.103 kcal/mol).  
 
Figure 13. Binding of dasatinib (green) to Abl kinase (magenta). Potential hydrogen bonds 
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Figure 14. Charge optimization results and sensitivity analysis of dasatinib in complex with 
WT Abl. A) Optimal charge distribution of dasatinib when bound to WT Abl. Charges range 
from -1.0e (red) to 1.0e (blue). Hydrophobic atoms are colored in white. Total charge on drug is 
constrained to be 0. B) Charge differences of dasatinib bound to WT between optimal and 
natural charges. Red indicates atoms that are too positive and would be more optimal if they 
were more negative. Blue indicates atoms that are too negative and would be more optimal if 
they were more positive. 
 
 After charge optimization (figure 14), the free energy of binding showed an improvement 
of 5.57 kcal/mol. Just as with the two previous early generation drugs, when the monopole of the 
drug is constrained to 0.0e, the drug’s optimal charge distribution is largely hydrophobic. Only 
the aminothiazole group (moiety 4), parts of the piperazine group (moiety 2), and the hydroxyl 
group of moiety 1 are polar. Figure 14b shows that the aminothiazole, which interacts with 
Met318 via two hydrogen bonds, is already very close to its optimal charge distribution. As well, 
the piperazine group is close to optimal. Moreover, our sensitivity analysis suggests that the free 







Wants to be positiveWants to be negative
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 Component analysis results (figure 12) indicate that the amide group (moiety 5, O27, C3, 
N22, H37) contributes very unfavorably to binding. This seems to contradict the idea that this is 
a key interaction in the binding of dasatinib to Abl kinase. However, the partial atomic charges 
on the amide are fairly optimal (figure 14b), suggesting that nearly any other charge distribution 
on the amide would be even more unfavorable. This is discussed in more detail later. 
Additionally, the free energy of binding is slightly sensitive to changes in charge on atoms H37 
and O27 of the amide. However, the hydroxyl group in moiety 1 is furthest from its optimal 
charge distribution. In fact, atoms O33 and H56 are oppositely charged from its natural charges 
when optimized: when optimal, O33 is slightly positive, while H56 is negatively charged.  
An unconstrained optimization found the optimal monopole for the drug to be 6.6e. The 
free energy of binding improved by 16.608 kcal/mol (table 2). This represents an additional gain 
of 11.018 kcal/mol from the constrained optimization. The rather high magnitude of the optimal 
monopole is surprising and seems physically unrealistic, even given the constraints applied. This 
will be further addressed in the discussion section. 
 
Third Generation Drugs 
In this section, we present data on two third generation drugs that bind to both the WT 
and T315I mutant.  
Ponatinib 
Ponatinib, a novel therapeutic drug developed by Ariad Pharmaceuticals, shows promise 
in battling drug resistance conferred by T315I mutant.  
 
	   39	  
 
Figure 15. Structure of ponatinib and component analysis show favorable and unfavorable 
moieties of the drug to WT and mutant Abl kinase. A) Structure of ponatinib colored by atom 
type. Atoms are labeled. B) Component analysis was conducted on each chemical moiety 
(separated by pink bonds) of ponatinib while bound to WT. C) Component analysis was 
conducted on each chemical moiety of ponatinib while bound to T315I mutant. Favorability of 
moiety indicated with color and intensity. White represents neutral moieties, red represents 
unfavorable moieties, and blue represents favorable moieties. ΔΔGmoiety are labeled. 
 
 Like earlier generation drugs, ponatinib interacts with a few key residues on the Abl 
binding interface (see Figure 16 below). However, ponatinib bypasses any interaction with 
Thr315 or Ile315. Moiety 6 (acetylene) is closest to residue 315 in both WT and mutant 
complexes. Component analysis results (figures 15b, 15c) on moiety 6 show that it does not 
contribute significantly favorably or unfavorably to binding (|ΔΔGmoiety,6| < 1 kcal/mol). 
Component analysis shows us that moiety 1 (methylpiperazine) is highly unfavorable to binding 
in both WT and mutant complexes: ΔΔGmoiety,1,WT = -1.749 kcal/mol; ΔΔGmoiety,1,T315I = -1.880 
kcal/mol. In both the WT and mutant complex, two groups contribute significantly favorably to 
binding: moiety 4 and 7. Like imatinib and nilotinib, the amide group, or moiety 4, interacts via 
two hydrogen bonds with Glu286 and Asp381 (figure 16). Component analysis reveals that this 
amide group contributes favorably (over 2 kcal/mol) in both mutant and WT complex. Similarly, 
66G = -1.749 kcal/mol
66G = 0.792 kcal/mol
66G = -0.097 kcal/mol
66G = 1.375 kcal/mol
66G = -0.622 kcal/mol
66G = 0.583 kcal/mol

















































































66G = -1.88 kcal/mol
66G = 0.988 kcal/mol
66G = -0.0425 kcal/mol
66G = 1.381 kcal/mol
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66G = 0.593 kcal/mol
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moiety 7, which interacts with the backbone of Met318, contributes favorably (over 1 kcal/mol) 
in both mutant and WT complex.  
 
 
Figure 16. Binding of ponatinib (green) to A) WT Abl kinase (magenta) and B) T315I 
mutant Abl kinase. Potential hydrogen bonds are displayed in red dotted lines. Interacting 
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Figure 17. Charge optimization results and sensitivity analysis of ponatinib in complex with 
WT Abl. A) Optimal charge distribution of ponatinib when bound to WT Abl. Charges range 
from -1.0e (red) to 1.0e (blue). Hydrophobic atoms are colored in white. Total charge on drug is 
constrained to be 0. B) Charge differences of ponatinib bound to WT between optimal and 
natural charges. Red indicates atoms that are too positive and would be more optimal if they 
were more negative. Blue indicates atoms that are too negative and would be more optimal if 
they were more positive. 
 
 Ponatinib was optimized to bind maximally to the WT Abl kinase. Charge optimization 
yielded an improvement of 10.139 kcal/mol. With the monopole of the drug constrained to 0.0e, 
several parts of ponatinib are optimal when hydrophobic. In particular, moieties 5 and 6 are both 
hydrophobic and already close to optimal in its natural charge distribution. The methylpiperazine 
group (moiety 1) has high magnitude partial atomic charges in its optimal charge distribution 
(indicated by the white and blue colored atoms in Figure 17a). However, in addition to 
contributing unfavorably to binding, moiety 1 is also far from its optimal charge distribution. 
This suggests that moiety 1 can be improved to contribute less unfavorably to binding. 
1.0e0.0e-1.0e 1.0e0.0e-1.0e
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Furthermore, the free energy of binding is highly sensitive to changes in charge on the atoms of 
the methyl group in moiety 1. Moiety 3 (atoms O28, C27, N29, and H56) interacts with both 
Asp381 and Glu286, just as earlier generation drugs do. The amide group is highly polar and 
already close to optimal. Similarly, moiety 7’s nitrogen (N1) is highly charged when optimized. 
Figure 17b shows that N1 is already optimal; N1 interacts with the backbone NH of Met318.   
An unconstrained optimization yielded an optimal monopole of the drug to be 1.6e 
kcal/mol when bound to the WT, improving the free energy of binding by 12.039 kcal/mol (table 
2). This yields an additional gain in favorability of 1.9 kcal/mol.  
 
Figure 18. Charge optimization results and sensitivity analysis of ponatinib in complex with 
T315I mutant Abl. A) Optimal charge distribution of ponatinib when bound to T315I mutant 
Abl. Charges range from -1.0e (red) and 1.0e (blue). Hydrophobic atoms are colored in white. 
Total charge on drug is constrained to be 0. B) Charge differences of ponatinib bound to mutant 
Abl between optimal and natural charges. Red indicates atoms that are too positive and would be 
more optimal if they were more negative. Blue indicates atoms that are too negative and would 
be more optimal if they were more positive. 
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 Ponatinib was also optimized to bind with maximal tightness to T315I mutant Abl kinase. 
Charge optimization yielded an improvement of 8.83 kcal/mol (figure 18). Like ponatinib bound 
to the WT Abl kinase, much of the drug is hydrophobic when optimized. All except moieties 1 
and 4 show an optimal distribution of mostly hydrophobic atoms (figure 18a). The methyl-
piperazine group (moiety 1) contributes unfavorably to binding and shows an optimal charge 
distribution with charged atoms, especially atoms N39 and C15, both of which indicate optimal 
charges of close to positive 1.0e. These two atoms are also very far from their optimal charge 
distribution (figure 18b).  
  Another optimally charged group is moiety 4, the amide (atoms O28, C27, N29, and 
H56). This group interacts with the side chains of Asp381 and Glu286 and shows an optimally 
polar charge distribution. Sensitivity analysis shows that the free energy of binding is highly 
sensitive to changes in O28’s charge. Figure 18b shows that moiety 4 is already quite optimal.  
Moiety 7’s N1 atom, which interacts with the backbone of Met318, is very polar and 
fairly close to being optimally charged. Finally, atom C33 in moiety 3 is quite far from optimal 
(indicated by the intense red color in Figure 18b). In its optimal charge distribution, moiety 3 is 
overall hydrophobic.  
An unconstrained optimization was also applied to this system, yielding an optimal 
monopole of the drug to be 2.02e. The free energy of binding was improved by 12.781 kcal/mol 
(table 2), yielding an additional gain of 3.951 kcal/mol.  
 
PPY-A 
PPY-A is a pyyropyridine inhibitor, binding to both the T315I mutant and WT Abl kinase 
(Figure 20 shows the binding site and key interacting residues for both). It is also worth noting 
that PPY-A binds to the active form of the Abl kinase, like dasatinib.  
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Figure 19. Structures of PPY-A and component analysis show favorable and unfavorable 
moieties of the drug. A) Structure of PPY-A colored by atom type. Atoms are labeled. B) 
Component analysis was conducted on each chemical moiety (separated by pink bonds) of 
ponatinib while bound to WT. C) Component analysis was conducted on each chemical moiety 
of PPY-A while bound to T315I mutant. Favorability of moiety indicated with color and 
intensity. White represents neutral moieties, red represents unfavorable moieties, and blue 
represents favorable moieties. ΔΔGmoiety are labeled. 
 
 Like ponatinib, PPY-A bypasses interacting with residue 315 in both the WT and mutant 
complexes. Interestingly, almost all moieties contribute favorably to binding in PPY-A to both 
mutant and WT Abl kinase (figures 19b, 19c). The favorable moieties all form hydrogen bonds 
with at least one residue on Abl kinase (figure 20). Moiety 5, or the ether group, contributes 
slightly unfavorably to binding, but with |ΔΔGmoiety,6| < 1 kcal/mol, we cannot say that it is 
significantly unfavorable. Between the WT and mutant complex, all moieties except moiety 4 
contribute more significantly in the mutant complex than the WT complex. For example, 
ΔΔGmoiety,1,WT = 0.528 kcal/mol, while ΔΔGmoiety,1,mutant  = 1.089 kcal/mol; ΔΔGmoiety2,WT = 0.199 
kcal/mol, while ΔΔGmoiety,2,mutant = 0.919 kcal/mol. PPY-A’s methyl-ether group, or moiety 5, 
contributes more unfavorably in the WT than the mutant (ΔΔGmoiety,5,WT = -0.229 kcal/mol; 
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Figure 20. Binding of PPY-A (green) to A) WT Abl kinase (magenta) and B) T315I mutant 
Abl kinase (blue). Potential hydrogen bonds are displayed in red dotted lines. Interacting 
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Figure 21. Charge optimization results and sensitivity analysis of PPY-A in complex with 
WT Abl. A) Optimal charge distribution of PPY-A when bound to WT Abl. Charges range from 
-1.0e (red) to 1.0e (blue). Hydrophobic atoms are colored in white. Total charge on drug is 
constrained to be 0. B) Charge differences of PPY-A bound to WT between optimal and natural 
charges. Red indicates atoms that are too positive and would be more optimal if they were more 
negative. Blue indicates atoms that are too negative and would be more optimal if they were 
more positive. 
 
PPY-A was optimized to bind to WT Abl kinase. Charge optimization yielded an 
improvement of 2.85 kcal/mol (figure 21). While much of the drug is optimal when hydrophobic, 
the moiety 1’s hydrogens (H46, H47, H48) are very polar in its optimal charge distribution. They 
are also far from optimal. This suggests that this portion of the drug can potentially be improved. 
Another notable polar section of the drug is atoms N1 and C6 in moiety 3. As part of the double-
ring aromatic group, these atoms are naturally close to their optimal charge distribution. N1 and 
H37 interact via hydrogen bonds with residues Met318 and Glu316, respectively.  
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An unconstrained optimization was also applied to this system, yielding an optimal 
monopole of the drug to be 3.61e. This optimization improved the free energy of binding by 
8.769 kcal/mol (table 2), which is an additional gain in favorability of 5.919 kcal/mol.  
 
 
Figure 22. Charge optimization results and sensitivity analysis of PPY-A in complex with 
T315I mutant Abl. A) Optimal charge distribution of PPY-A when bound to mutant Abl. 
Charges range from -1.0e (red) to 1.0e (blue). Hydrophobic atoms are colored in white. Total 
charge on drug is constrained to be 0. B) Charge differences of PPY-A bound to mutant Abl 
between optimal and natural charges. Red indicates atoms that are too positive and would be 
more optimal if they were more negative. Blue indicates atoms that are too negative and would 
be more optimal if they were more positive. 
 
Similarly, PPY-A was optimized to bind to T315I mutant Abl kinase. This yielded an 
improvement in the free energy of binding to be 2.99 kcal/mol. When compared to the WT 
complex, more of PPY-A is polar when optimized to bind to the mutant Abl kinase. Two 
moieties show a difference between the optimal and natural charge distribution: moieties 1 and 2. 
The methyl group of moiety 1, again (H46, H47, H48, C27), proved to be polar when optimized. 
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The carbonyl group of moiety 1 (C23, O24) is also extremely polar. The carbonyl interacts with 
the backbone of Gly249 in a hydrogen bond and is moderately far from optimal. Moiety 2, the 
pyrimidine, also contains highly charged atoms in its optimal charge distribution. Atoms C20 
and C21 are more positive and negative, respectively, in their optimal charge distribution and are 
far from their optimal charges.  
An unconstrained optimization was also applied to this system, yielding an optimal 
monopole of the drug to be 2.62e. The free energy of binding improved by 7.797 kcal/mol (table 
2). This is is an additional gain of 4.807 kcal/mol from the constrained optimization. 
Both the WT and mutant complexes interact with the same residues via hydrogen bonds 
and have no apparent interactions with residue 315. The portions of the drug near residue 315 







































2HYY 13.818 3.375 1.457 1.144 n/a n/a n/a 1.092 
3CS9 9.064 4.517 2.469 2.267 n/a n/a n/a 2.093 
2GQG 8.16 2.570 -0.111 -2.531 -4.629 -8.338 -8.399 -8.448 
3OXZ 12.461 2.322 0.667 0.494 1.305 n/a n/a 0.422 
3IK3 11.69 2.842 -0.059 -1.091 -0.163 n/a n/a -1.091 
2QOH 6.769 3.919 1.436 -0.452 -1.724 n/a n/a -2.000 
2Z60 6.497 3.531 1.041 -0.842 -1.129 n/a n/a -1.300 
Table 2. Free energy binding calculations of optimized structures subject to various total 
monopole constraints (all values in kcal/mol). All structures were optimized subject to total 
monopole constraints of 0, 1e, and 2e. Drugs with optimal overall monopoles of greater than 2e 
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DISCUSSION 
 
In this study, we systemically applied the computational techniques of charge 
optimization and component analysis to probe the electrostatic interaction between chronic 
myeloid leukemia drugs and their biological target, the Abl kinase. We comparatively analyzed 
three DFG-out inhibitors, imatinib, nilotinib, and ponatinib, which bind to the inactive 
conformation of the Abl kinase. We also analyzed two DFG-in inhibitors, dasatinib and PPY-A, 
which bind to the active conformation of the Abl kinase. Of these drugs, only ponatinib and 
PPY-A remain potent against the T315I mutant Abl kinase. While this study focused on the 
electrostatic interactions, it is worth noting that each drug forms key van der Waals and aromatic 
interactions with the Abl kinase in the hydrophobic binding pocket as well. 
DFG-out inhibitors imatinib, nilotinib, and ponatinib form hydrogen bonds with residues 
Glu286, Met318, and Asp381 on the Abl kinase (figures 2, 10, 16). The amide moieties on each 
drug that interact with Asp381 and Glu286 are already quite optimal to binding in their natural 
charge distributions (figures 8, 11, 17, 18), suggesting that these are key moieties to conserve 
when generating novel drugs for CML. This amide moiety contributes favorably to binding in all 
three drugs.  
To further investigate the role of these key residues in the interaction with CML drugs, 
we also performed component analysis on the Abl residues Glu286, and Asp381 for each CML 
drug-Abl kinase complex. While component analysis on Glu286 did not reveal any significantly 
favorable or unfavorable contribution to binding, Asp381 yielded an unfavorable |ΔΔG381| of 
greater than 1 kcal/mol for all DFG-out drugs. Asp381 forms a hydrogen bond with the amide 
carbonyl with all three drugs, intuitively suggesting that Asp381 might contribute favorably to 
binding. Upon closer examination, we find that Asp381 pays a heavy desolvation penalty in 
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DFG-out inhibitors (2.33 – 3.64 kcal/mol). Thus, when rendered into its hydrophobic isostere, 
while the interaction with each drug’s amide carbonyl is weakened, the dampened desolvation 
penalty of a hydrophobic residue 381 improves the overall free energy of binding. However, it is 
worth noting that while Asp381 contributes unfavorably to binding due to its desolvation 
penalty, the amide moiety it interacts with contributes favorably to the binding reaction. Thus, 
though the receptor’s contribution might be electrostatically unfavorable, the optimal nature of 
the drug suggests that any other drug moiety or charge distribution could be even more 
unfavorable. Additionally, this interaction could possibly contribute to the specificity of this 
drug.57  
DFG-in inhibitors dasatinib and PPY-A bind in the more flexible active conformation of 
the Abl kinase. Interestingly, dasatinib and PPY-A interact with different residues on the Abl 
kinase (figures 13 and 20). Dasatinib interacts heavily with the backbone of Met318 via two 
hydrogen bonds through the N of the thiazole group and NH of the amino group. Similarly, PPY-
A forms key hydrogen bonds with Met318 and other residues on the Abl kinase. Specifically, the 
two nitrogen atoms in the pyrrolopyridine core of PPY-A (moiety 3 in figure 19) interact with 
the backbone NH of Met318 and carbonyl O of Glu316. Furthermore, the N of the pyridine 
group (moiety 2) forms a hydrogen bond with the side chain of Asn322; finally, the carbonyl O 
of dimethylaminocarbonyl group (moiety 1) interacts with the backbone N of Gly249 in the 
glycine-rich loop of the Abl kinase.  
Qualitatively, the differential binding interactions between PPY-A and the other drugs 
included in this study indicate potential future direction for future improvement in designing 
drugs to target not just the hydrophobic binding pocket of the Abl kinase used by previous drugs, 
but also the other areas of the ATP-binding pocket, including the Gly-rich loop, to gain 
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selectivity and tight binding. To study the electrostatic interaction between the Gly-rich loop 
residue Gly316 and PPY-A, we set the charges of that residue to zero and recalculated the free 
energy of binding. We found that this interaction with a residue in the Gly-rich loop is very 
favorable to binding (ΔΔG316 > 2 kcal/mol). The interacting partner on PPY-A (the 
pyyrolopyridine core, moiety 3) similarly contributes favorably to binding in both the WT and 
mutant complex (ΔΔGmoiety3 > 1 kcal/mol). These mutually favorable interactions can be 
capitalized on in future generation drugs. Indeed, Zhou et al.’s structural analysis of PPY-A 
showed potent activity and tight binding to the T315I Abl mutant kinase.1  
Interestingly, whether the drug is a DFG-out or DFG-in inhibitor, each drug in this 
comparative study forms key hydrogen bonds with Met318. Furthermore, the moieties of each 
drug that interact with the backbone of Met318 are already optimal to yield the most favorable 
electrostatic free energy of binding. To confirm our charge optimization findings, we also 
conducted component analysis on Met318, finding that in all drug complexes except nilotinib, 
Met318 contributes very favorably to binding (ΔΔG318 ranges from 1 - 2 kcal/mol; for nilotinib 
ΔΔG318 = -0.1225 kcal/mol). Dasatinib in particular forms two hydrogen bonds with Met318; 
component analysis yielded ΔΔG316 > 2 kcal/mol. Because of the nature of backbone interaction 
with Met318, it is unclear whether or not mutations at this position will confer any resistance. No 
current point mutations at Met318 have been documented. This may be because in the normal 
function of the Bcr-Abl kinase, the backbone of Met318 interacts with N1 of ATP.8 Thus, point 
mutations on residue 318 may completely eliminate the activity of the Abl kinase. However, this 
residue warrants further investigation. 
In conducting this comparative study of five CML drugs, we also found some conserved 
moieties in the drugs, including a methylpiperazine group in ponatinib and imatinib. A moiety 
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often used for solubilization, this methylpiperazine group in ponatinib and imatinib contributes 
highly unfavorably to binding (figures 7 and 15). Furthermore, charge optimization shows that 
these groups are also highly suboptimal for binding (figures 8,17, and 18). While this group 
helps make the drug soluble and thus feasible as a CML therapy, it is worth noting that nilotinib, 
which was rationally improved from computational and structural studies of imatinib15, no longer 
has this group. Instead, the methylpiperazine was replaced with a methyl-imidazole group. Thus, 
the methylpiperazine in imatinib and ponatinib can potentially be altered to significantly improve 
binding and retain solubility properties of the drug.  
Interestingly, dasatinib also possesses a piperazine moiety in its structure. However, 
component analysis shows that piperazine does not contribute significantly favorably or 
unfavorably to the electrostatic binding interaction. The free energy of binding, however, is very 
sensitive to changes in charge on the piperazine’s atoms. Because of the high degree of 
sensitivity of the binding free energy, we can speculate that this moiety could potentially 
contribute favorably to binding if altered.  
 In addition, trifluoromethane is common in both ponatinib and nilotinib. Fluorinated 
compounds are often used in drug design, as it confers greater membrane permeability. They are 
also harder to oxidize, thus increasing the half life of the drug after consumption.58 To quantify 
the effects of the trifluoromethane on binding, we investigated the moiety with component 
analysis, revealing that in both ponatinib (WT and mutant) complexes and nilotinib complex, the 
contribution of trifluoromethane to the electrostatic portion of binding is negligible.  
Finally, we would like to highlight the T315I mutation and the important role of 
electrostatics in the relatively hydrophobic binding pocket of Abl kinase. First and second 
generation drugs imatinib and nilotinib form key hydrogen bonds with the gatekeeper residue 
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Thr315. In addition to the steric clash introduced by the bulkier side chain of Ile, the mutation 
from Thre315 to Ile315 also eliminates this key hydrogen bond with the side chain OH of Thr. 
Previous studies and phase 2 trials have confirmed imatinib’s14,21,59 and nilotinib’s60,61 lack of 
activity against T315I Abl kinase. Like imatinib and nilotinib, dasatinib also forms a hydrogen 
bond with gatekeeper residue Thr315’s OH via the NH of the drug’s amide. However, upon 
mutation to Ile315, dasatinib loses efficacy against battling CML in patients.59,62 Charge 
optimization (figure 14b) shows that the amide is already fairly close to optimal to yield the most 
favorable electrostatic binding free energy, suggesting that any other charge distribution would 
be worse for binding. However, this amide is not optimal in either imatinib or nilotinib. Future 
work should focus on a more detailed analysis of this particular interaction in various drugs.  
Both PPY-A and ponatinib show potent activity against mutant T315I Abl kinase. These 
third generation drugs bypass any interaction with the residue at position 315. Ponatinib uses its 
ethynyl group (moiety 6) to avoid contact with the bulky Ile in T315I mutant. Component 
analysis on this group reveals that it does not contribute significantly favorably or unfavorably to 
the electrostatic portion of binding. Similarly, component analyses on nearby residue T315 and 
I315 on the WT and mutant complex respectively show that neither residue contributes 
significantly to binding either. Taken together, these results suggest a lack of interaction between 
ponatinib and residue 315. Ponatinib may capitalize on interactions with other residues to inhibit 
the Abl kinase, rendering it effective against both the WT and T315I mutant. Analysis of PPY-A 
reveals a similar theme in binding to Abl kinase while bypassing interaction with residue 315.  
 Despite numerous other hydrogen bonding and hydrophobic interactions with the Abl 
kinase binding pocket, the point mutation T315I is enough to render the early generation drugs 
almost useless against CML. For example, though dasatinib forms two important hydrogen 
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bonds with Met318 and one hydrogen bond with Thr315, the mutation to Ile315 is enough to 
confer resistance of CML to dasatinib. Similarly, other early generation drugs imatinib and 
nilotinib also lose efficacy to the T315I mutant Abl kinase. While studies14,63 have proposed the 
loss of hydrogen bond in the T315I mutant as a cause of loss in treatment sensitivity to imatinib, 
no study has systematically analyzed residue 315 across multiple drugs. In contrast to this 
hypothesis, an MD simulation of T315I Abl kinase with imatinib indicates the major cause of 
resistance to be conformational changes resulting from the mutation rather than the loss of 
hydrogen bond to Thr 315.64 However, currently no crystallographic data on early generation 
drugs and T315I Abl kinase exists on the Protein Databank. Future steps of this project include 
conducting a docking study, in which we can build a T315I mutant model and dock imatinib, 
nilotinib, and dasatinib into the binding site to investigate the effects of the T315I mutation in the 
electrostatic portion of binding to these inhibitors. 
 Currently, the most common mutations found in clinical treatment of CML are at seven 
residue positions (250, 254, 255, 315, 351, 359, and 396), with T315I being the most resistant 
mutation.65 Given the differential binding interactions of different existing drugs, CML therapy 
could potentially include specific drug cocktails with previous generation drugs and future 
generation drugs to encompass as much interaction as possible with the Abl kinase. Already, 
second generation drugs such as dasatinib and nilotinib are used in conjunction with frontline 
therapy imatinib to battle resistance.14, 66  
 Upon unconstrained charge optimization, we found each drug’s optimal overall 
monopole to be quite high, ranging from 1.60e to as large as 6.60e. DFG-in inhibitors imatinib 
and nilotinib had an optimal overall monopole of 1.67e and 1.60e respectively when bound to the 
WT Abl kinase. Ponatinib had an optimal overall monopole of 1.60e to the WT and 2.02e to the 
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mutant Abl kinase. The original Abl kinase has an overall monopole of -7 to -10, depending on 
the missing residues in the crystal structure (described in methods section). The binding interface 
of Abl includes charged residues Glu286, Lys271, Asp381, and His361. One speculation may be 
that the long-range electrostatic effects of the overall negative Abl may affect the overall optimal 
monopole of the drug.  
 DFG-out inhibitors dasatinib and PPY-A are more difficult to rationalize. Dasatinib’s 
overall optimal monopole is extremely positive (6.6e), while PPY-A’s is 3.61e when optimized 
to the WT and 2.62e when optimized to the mutant Abl kinase. These values are substantially 
more positive than the optimal overall monopoles of the DFG-in inhibitors. This may be a result 
of the distinction between inactive and active conformations of the Abl kinase. In dasatinib and 
PPY-A’s case, only polar (non-charged) residues at the binding site interact with these drugs. In 
contrast, imatinib, nilotinib, and ponatinib interact with charged residues Glu286 and Asp381. 
Because dasatinib and PPY-A are less buried in the binding interface, these DFG-in inhibitors 
may be more influenced by the long-range electrostatic effect of the overall negative Abl kinase, 
making its optimal monopole more positive. It is also worth noting that the overall charge on the 
Abl kinase structures bound to dasatinib and PPY-A are more negative due to missing density of 
the crystal structure. Thus, the high magnitude of the optimal overall monopole of dasatinib and 
PPY-A may be an artifact of crystallographic missing density.  
 Interestingly, dasatinib’s overall optimal monopole is significantly higher at 6.6e. Upon 
closer examination, a few atoms dominate by adopting the highest possible charge given the 
constraints: 1.0e. These atoms are: C17, C31, H49, H52, H54, and H56. In figures 12 and 14, we 
see that the free energy of binding shows very low sensitivity to changes in these atoms. The 
carbons belong to the piperazine group, and the hydrogens belong to both the piperazine and 
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methanol group. We find that these atoms do not experience much desolvation upon binding; in 
both the bound and unbound states, they are exposed to solvent. Thus, an optimization may 
overcompensate with a high interaction term for the lack of desolvation. This could generate 
physically unrealistic high partial atomic charge magnitudes on those atoms. More investigation 
and follow-up studies are required to fully understand the implications of dasatinib’s high 
proclivity to a positive monopole.  
 Despite the unconstrained optimization results that indicate the optimality of positively 
charged drugs, small molecule inhibitors with an overall monopole is often physiologically 
undesirable. While this ultimately depends on the nature of the treatment, charged drugs have 
difficulty permeating the bilipid cell membrane. Furthermore, the overall charge on a drug 
affects solubility and kinetics as well.33 
 We must note that this study only investigates the electrostatic portion of binding. As 
mentioned above, other components of binding also affect the binding of CML drugs to the Abl 
kinase, including aromatic and hydrophobic interactions. Experimental studies have shown a 
decrease in binding affinity between imatinib and T315I mutant relative to the WT Abl kinase.67 
Furthermore, experimental data confirms our free energy of binding calculations that nilotinib 
binds more tightly to the WT Abl than imatinib.67 However, binding assays show a significant 
difference in binding of ponatinib to the WT and mutant Abl kinase.17 While our electrostatic-
only calculation revealed a slight improvement in binding to the mutant Abl, ponatinib shows a 
five to seven fold reduction in inhibitory efficacy to the mutant relative to the WT. Thus, while 
electrostatics is often used to better understand the binding of drugs to their biological targets 
computationally, future studies that encompass other components of binding will be needed to 
quantitatively link computational analyses to experimental data.  
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 Though it is beyond the scope of this work, our results could be extended with a 
molecular dynamic simulation. Our study assumes rigid binding. However, as mentioned 
previously, the Abl kinase can undergo conformational change upon binding to either DFG-in or 
DFG-out inhibitors.64 Future studies should apply charge optimization to molecular dynamic 
simulation structures, accounting for the conformational flexibility of the binding site when 
studying the electrostatics of binding within this system.  
 Additionally, as with previous studies that used charge optimization theory, it would be 
advantageous to calculated root mean square deviations between the actual and optimal charge 
distributions of each drug to provide a quantitative comparison to complement the visual 
inspections of the figures. Future work should quantify how optimal a charge is.  
 Finally, it is worth noting that we conducted our study in the absence of salt in the 
solvent. To address this potential discrepancy, we conducted a free energy binding calculation of 
imatinib with WT Abl in salt, yielding a difference between salt and non-salt calculations to be 
0.06 kcal/mol. Follow up experiments should investigate the effect of salt on charge optimization 
and component analysis. Future studies should take into account salt in the solvent, especially 
because salt screens electrostatic interactions and therefore could potentially yield artificially 
high optimal monopoles when considering long-range interaction target monopoles.  
In this study, we identified highly conserved moieties of drugs that contribute favorably 
to binding. In particular, while previous drugs failed to capitalize on the Gly-rich loop of the 
active conformation, this is a future direction that could potentially guide better development of 
novel CML therapeutics. Even after identifying moieties of a drug that could potentially be 
altered to improve binding, there are inherent challenges in proposing a modification that 
maintains the integrity of the drug’s structure while altering the partial atomic charges to reflect 
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the optimal distribution. Furthermore, changing a functional group may reduce solubility or 
introduce other pharmacologically unfavorable properties to the drug. Nevertheless, these 
potential alterations may provide a future direction for ration drug design.  
Taken together, this study analyzes the differential binding interactions of five CML 
drugs. To the best of our knowledge, this is the first study that systematically investigates the 
interactions of DFG-out and DFG-in inhibitors with both WT and mutant Abl kinase through 
charge optimization, component analysis, and sensitivity analysis. We hope that this study will 
provide some insight that may help facilitate understanding of the principles of electrostatic 
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